CME ACTIVITY NO. IN08-009
Therapeutic Strategies for Antiretroviral Treatment Experienced Patients: A Case Based Update - Internet
2008
Participant Information
First Name
Last Name
Degree
Address
City, State, Zip
Telephone
Fax
E-Mail (CME Certificate sent by E-Mail)
Rush Medical College Alumnus
Year of Graduation
________ Indicate the number of credits that you are requesting for this educational activity. You should claim only credit commensurate with the
extent of your participation in the activity.
Please evaluate the level of achievement of this CME activity. Match the number on the right to the questions, and fill in the appropriate circle, using a
#2 pencil, according to the following scale:
1.
    
5 = Excellent
4 = Good
3 = Fair
2 = Poor
1 = Unsatisfactory
2.
    
Rate each faculty member on his/her content, presentation, audio/visuals, and syllabus.
Paul Sax, MD
Content
1.
Presentation
2.
A/V
3.
Syllabus
4.
Evaluate how well this activity addressed the stated objectives.
5.
6.
7.
8.
9.
Describe the effective use of currently approved ARVs in treatment-experienced patients.
Discuss recent clinical trial data on new ARV agents, including those from existing and novel classes.
Describe the benefits, risks and alternatives regarding the use of newer therapies in ARV-experienced
patients.
Discuss the issues surrounding the timing for starting a new regimen or therapy in ARV-experienced
patients.
Describe the connection between the risks associated with low-level viremia and development of
resistance.
Please use the following scale to respond to the following questions:
Agree
Disagree
5
4
3
2
1
In thinking about implementing these objectives, rate the following:
10.
11.
12.
13.
14.
15.
16.
My patient mix is appropriate for the strategies.
My office and practice systems can accommodate these changes.
My patients will have trouble complying with these changes/strategies.
These changes are too time consuming.
I am so comfortable with my current approach it will be difficult to change.
My current office and practice systems are very difficult to change.
The medications/procedures discussed are not available for my patients.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
In thinking about the issues raised in this educational activity, rate your degree of agreement with each
statement below:
24.
25.
17. On average, I utilized the patient care/treatment strategies described in this educational activity prior to my
participation in this educational activity.
18. I plan to implement the patient care/treatment strategies described.
26.
27.
28.
19. This CME activity was free of commercial bias for or against any product. If you perceived any bias please
provide specific comments below.
20. The course satisfied your reason for taking it.
21. The course was well organized and presented.
22. Please comment on the strengths/weaknesses of this activity; future topics, improvements, etc.
_______________________________________________________________________________________
5 = Excellent
4 = Good
3 = Fair
2 = Poor
1 = Unsatisfactory
Rate each faculty member on his/her content, presentation, audio/visuals, and syllabus.
July, 2007
29.
30.












































































































































THERAPEUTIC STRATEGIES FOR ANTIRETROVIRAL EXPERIENCED
PATIENTS:
A Patient with Multi-regimen Failure
1. A nucleoside analog combination that should generally be avoided is tenofovir plus:
a. Zidovudine
b. Abacavir
c. Didanosine
d. Lamivudine
2. Tenofovir is not significantly more active than placebo if ≥3 thymidine associated
mutations are present and these mutations include:
a. Y181C
b. M41L
c. K70R
d. D67N
3. Patients with NNRTI resistance from past NNRTI experience are unlikely to have >2
etravirine mutations
a. True
b. False
4. In the TITAN study, darunavir/r was significantly more likely than lopinavir/r to suppress
antiretroviral experienced patients to <50 copies/mL at 48 weeks
a. True
b. False
5. Maraviroc provides significantly higher suppression of HIV RNA than placebo in patients
who have predominantly R5 virus, with only low level amounts of X4.
a. True
b. False
PLEASE COMPLETE THE TWO SETS OF QUESTIONS AND RETURN VIA MAIL OR FAX TO:
ViralEd
Attention: Therapeutic Strategies Program
112 Dunkard Church Road
Stockton, NJ 08559
917-591-6353 (Fax)
July, 2007